Oncotype DX® Colon Recurrence Score

67-Year-Old Female Patient

with Stage III A/B (N1-3) tumor

Patient Details

Stage III A/B (N1-3)
Low (1)
Not Provided

Other Information:

Patient has hypertension, P.E

Treatment: Capecitabine (Xeloda) and Oxaliplatin

Clinical Experience

Prognosis for Stage III A/B Colon Cancer Patients Following Adjuvant Chemotherapy

The clinical validation study included patients from the NSAPB C-07 trial which randomized 409 stage III A/B patients to 5FU/LV versus 5FU/LV+oxaliplatin.1

The average 5 year risk of recurrence for patients who had a Recurrence Score® result of 13 was:

Other Considerations: The recurrence risk for patients with ≥ 12 nodes examined was lower than the risk for those with < 12 nodes examined.


1. Yothers et al. J Clin Oncol. 2013.

Disclaimer: These case studies are brought to you for educational purposes only and should not be interpreted as an endorsement of Exact Sciences or its services by the submitting physician, or any other product or therapy. The information is sometimes related to interpretive diagnostic opinions of the treating physicians, and is not intended to represent the “standard of care.” The case studies reflect real life cases of patients who have used Oncotype DX, however they are individual results and results do vary. The examples are not necessarily representative of all of those who will use our clinical tests. Exact Sciences does not endorse any of the contributors featured on this site.

Submit a Case

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus sodales ultricies elementum.

Online Ordering
& Reports

Login to the Physician Portal to place an order and view patient results.


To sign up, please call or email Customer Service at:
+1 (866) ONCOTYPE (866-662-6897)


Contact your Regional Oncogenomic Liaison for more information or to submit a case study.

Recurrence Score®13